Last Update: 2024-03-28 02:12:36
Coherus BioSciences Inc. ( CHRS ) https://www.coherus.com
United States
Historical Returns*:
*Assumes dividends reinvested
Market Stats:
Market Capitalization($MM)
Enterprise Value($MM)
Daily Volume(MM)
Valuation Metrics:
Price/Earnings Ratio
Price/Sales Ratio
Price/Book Value
FCF Yield(%)
Dividend Yield(%)
Profitability Stats:
Operating Margin %(ttm)
Gross Profit %(ttm)
EBITDA Margin %(ttm)
Shareholder Value Creation:
Cost of Capital %(est)
ROIC %(ttm)
ROCE %(ttm)
Other Earnings and Cash Flow Stats:
Coherus BioSciences Inc. ( CHRS ) Net Income TTM ($MM) is -273.52
Coherus BioSciences Inc. ( CHRS ) Operating Income TTM ($MM) is -231.69
Coherus BioSciences Inc. ( CHRS ) Owners' Earnings Annual ($MM) is -201.00
Coherus BioSciences Inc. ( CHRS ) Current Price to Owners' Earnings ratio is -1.28
Coherus BioSciences Inc. ( CHRS ) EBITDA TTM ($MM) is -226.54
Coherus BioSciences Inc. ( CHRS ) EBITDA Margin is -67.46%
Capital Allocation:
Coherus BioSciences Inc. ( CHRS ) has paid 0.00 dividends per share and bought back -34.58524 million shares in the past 12 months
Coherus BioSciences Inc. ( CHRS ) has reduced its debt by 232.856 million USD in the last 12 months
Capital Structure:
Coherus BioSciences Inc. ( CHRS ) Interest-bearing Debt ($MM) as of last quarter is 6
Coherus BioSciences Inc. ( CHRS ) Annual Working Capital Investments ($MM) are 4
Coherus BioSciences Inc. ( CHRS ) Book Value ($MM) as of last quarter is -194
Coherus BioSciences Inc. ( CHRS ) Debt/Capital as of last quarter is -4%
Other Balance Sheet Stats:
Coherus BioSciences Inc. ( CHRS ) has 102 million in cash on hand as of last quarter
Coherus BioSciences Inc. ( CHRS ) has 331 million of liabilities due within 12 months, and long term debt 226 as of last quarter
Coherus BioSciences Inc. ( CHRS ) has 112 common shares outstanding as of last quarter
Coherus BioSciences Inc. ( CHRS ) has 0 million USD of preferred stock value
Academic Scores:
Coherus BioSciences Inc. ( CHRS ) Altman Z-Score is -3.54 as of last quarter
Coherus BioSciences Inc. ( CHRS ) Piotroski Score is 4.00 as of last quarter
Corporate Governance:
Coherus BioSciences Inc. ( CHRS ) largest shareholder is owning shares at 0.00 ($MM) value
Dennis M Lanfear(an insider) Sold 223100 shares of Coherus BioSciences Inc. ( CHRS ) for the amount of $450662.00 on 2023-11-22
1.61% of Coherus BioSciences Inc. ( CHRS ) is held by insiders, and 92.78% is held by institutions
Coherus BioSciences Inc. ( CHRS ) went public on 2014-11-06
Other Coherus BioSciences Inc. ( CHRS ) financial metrics:
Unlevered Free Cash Flow:-135.05
Operating Margin:-42.92
Gross Profit Margin:100.00
Div. Payout Ratio%:0.00
Div. Growth YoY%:0.00
Equity Return%:81.98
Buffet's Owners Earnings:-201.00
Price to Owner's Earnings:-1.28
About Coherus BioSciences Inc. ( CHRS ) :
Coherus BioSciences, Inc., a biopharmaceutical company, focuses on the biosimilar and immuno-oncology market primarily in the United States. The company provides UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; and CIMERLI, a biosimilar to Lucentis, a biosimilar product interchangeable with Lucentis for the treatment of neovascular age-related macular degeneration, macular edema following retinal vein occlusion, diabetic macular edema, diabetic retinopathy, and myopic choroidal neovascularization in the United States. It also offers YUSIMRY, a biosimilar to Humira for the treatment of patients with inflammatory diseases characterized by increased production of tumor necrosis factor (TNF) in the body, including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, psoriasis, and ulcerative colitis. Coherus BioSciences, Inc. has license agreements with Selexis SA; AbbVie, Inc.; Pfizer, Inc.; Bioeq AG; and Shanghai Junshi Biosciences Co., Ltd. The company was formerly known as BioGenerics, Inc. and changed its name to Coherus BioSciences, Inc. in April 2012. Coherus BioSciences, Inc. was incorporated in 2010 and is headquartered in Redwood City, California.
User Content from Tickernomics. Created by Luminus.

This web site and its creators are not certified financial advisors. All opinions/suggestions expressed on this website should not be treated as specific inducement to make a particular investment or follow a particular strategy, but only as an expression of an opinion.The Company doesn't warrant the information provided on the website for its completeness or accuracy, and it should not be relied upon as such. The Company is not under any obligation to update or correct any information provided on this website.The content of this website is published in the United States of America and persons who access it agree to do so in accordance with applicable U.S. law.Past performance is not indicative of future results. The Company doesn't guarantee any specific outcome or profit. You should be aware of the real risk of loss in following any strategy or investment discussed on this website.Strategies or investments discussed may fluctuate in price or value. Investors may get back less than invested. Investments or strategies mentioned on this website may not be suitable for you. This material does not take into account your particular investment objectives,financial situation or needs and is not intended as recommendations appropriate for you. You must make an independent decision regarding investments or strategies mentioned on this website. Before acting on information on this website, you should consider whether it is suitable for your particular circumstances and strongly consider seeking advice from your own financial or investment adviser.